Vanda Pharmaceuticals Announces Fanapt® Patent

Pharmaceutical Investing

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) announces that a patent for Fanapt® was issued by the United States Patent and Trademark Office in October 2015. The patent is listed in the U.S. Food and Drug Administration publication Approved Drug Products With Therapeutic Equivalence Evaluations.

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) announces that a patent for Fanapt^®was issued by the United States Patent and Trademark Office in October 2015. The patent is listed in the U.S. Food and Drug Administration publication Approved Drug Products With Therapeutic Equivalence Evaluations.
According to the press release:

Prior to this newly listed patent, the Fanapt® Orange Book listed patents were the U.S. composition of matter patent, the ‘432 patent, the ‘610 patent, the ‘776 patent, the ‘638 patent, the ‘255 patent, the ‘742 patent, the ‘256 patent, and the ‘254 patent, expected to expire in November 2016, September 2025, November 2027, August 2030, October 2030, December 2030, January 2031, February 2031, and December 2031, respectively.

Click here to read the full press release from Vanda.

food and drug administration patent united states Company News